
National Health (Continued Dispensing) Determination 2012
as amended
made under subsection 89A(3) of the
National Health Act 1953
Compilation start date: 10 August 2013
Includes amendments up to: PB 45 of 2013
About this compilation
This compilation
This is a compilation of the National Health (Continued Dispensing) Determination 2012 as in force on 10 August 2013. It includes any commenced amendment affecting the legislation to that date.
This compilation was prepared on 21 November 2013.
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of each amended provision.
Uncommenced amendments
The effect of uncommenced amendments is not reflected in the text of the compiled law but the text of the amendments is included in the endnotes.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If a provision of the compiled law is affected by a modification that is in force, details are included in the endnotes.
Provisions ceasing to have effect
If a provision of the compiled law has expired or otherwise ceased to have effect in accordance with a provision of the law, details are included in the endnotes.
Contents
Part 1—Preliminary
1.01 Name of determination
1.02 Commencement
1.03 Definitions
1.04 Purpose
Part 2—Conditions
2.01 General
2.02 Not practicable to obtain prescription
2.03 Previous supply of pharmaceutical benefit
2.04 Stability of therapy
2.05 Prior clinical review by PBS prescriber
2.06 Prescription for last supply of pharmaceutical benefit
2.07 No continued dispensing in previous 12 months
2.08 Declaration by person supplied with pharmaceutical benefit
2.09 Maximum quantity of supply
2.10 Preparing and recording information
Part 3—Pharmaceutical benefits
3.01 Pharmaceutical benefits
Schedule 1—Pharmaceutical benefits
Part 1—Oral hormonal contraceptives
Part 2—Lipid modifying agents
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnote 5—Uncommenced amendments [none]
Endnote 6—Modifications [none]
Endnote 7—Misdescribed amendments [none]
Endnote 8—Miscellaneous [none]
This determination is the National Health (Continued Dispensing) Determination 2012.
This determination commences on 1 July 2012.
(1) In this determination:
Act means the National Health Act 1953.
PSA Guidelines means the document titled Guidelines for the Continued Dispensing of eligible prescribed medicines by pharmacists, issued by the Pharmaceutical Society of Australia, as the document exists on 1 July 2012.
requested supply: see subsection 2.01(1).
(2) In this determination, the following terms have the same meaning as in Part VII of the Act:
approved pharmacist
listed brand
PBS prescriber
pharmaceutical benefit
pharmaceutical item.
Schedule equivalent
This determination specifies the pharmaceutical benefits that may be supplied, and the conditions that must be satisfied when those pharmaceutical benefits are supplied, by an approved pharmacist without a current prescription, but on the basis of a previous prescription from a PBS prescriber.
(1) For paragraph 89A(3)(b) of the Act, this Part sets out the conditions that must be satisfied when making a supply (the requested supply) of a pharmaceutical benefit to a person under subsection 89A(1) of the Act.
(2) An approved pharmacist must consider the PSA Guidelines when:
(a) satisfying the conditions set out in this Part; or
(b) deciding whether those conditions are satisfied.
(3) In this Part:
(a) a reference to the person is a reference to the person who requested the supply of a pharmaceutical benefit under subsection 89A(1) of the Act; and
(b) a reference to the PBS prescriber is a reference to the PBS prescriber who most recently prescribed the supply of the pharmaceutical benefit to the person.
(c) a reference to “the pharmaceutical benefit” in sections 2.03, 2.05, 2.06 and 2.07 includes a pharmaceutical benefit that is Schedule equivalent.
A condition is that the approved pharmacist is satisfied that it is not practicable for the person to obtain a prescription for the pharmaceutical benefit from a PBS prescriber before the person needs the supply of the pharmaceutical benefit.
A condition is that the approved pharmacist is satisfied that:
(a) the person has previously been supplied the pharmaceutical benefit on the basis of a prescription from a PBS prescriber; and
(b) the PBS prescriber prescribed the supply of the pharmaceutical benefit for the person in at least one of the circumstances determined for that pharmaceutical benefit under paragraph 85(7)(b) of the Act.
Note: The circumstances determined under paragraph 85(7)(b) of the Act relate to pharmaceutical benefits that are relevant pharmaceutical benefits under section 88A of the Act.
A condition is that the approved pharmacist is satisfied that the person’s therapy is stable.
A condition is that the approved pharmacist is satisfied that:
(a) the person has been taking the pharmaceutical benefit regularly for an uninterrupted period; and
(b) since the start of that period, the PBS prescriber has assessed the person’s condition and decided that there is a need for ongoing treatment with the pharmaceutical benefit.
Note: See paragraph 2.01(3)(b) for references to the PBS prescriber.
A condition is that the approved pharmacist is satisfied that the person had a valid prescription under Part VII of the Act for the last supply of the pharmaceutical benefit to the person before the requested supply.
A condition is that the approved pharmacist is satisfied that the person was not supplied with the pharmaceutical benefit under subsection 89A(1) of the Act in the 12 months before the requested supply.
A condition is that the person, or an agent of the person (other than the approved pharmacist), signs a declaration acknowledging that the person is being supplied with the pharmaceutical benefit without the presentation of a valid prescription under Part VII of the Act.
A condition is that the approved pharmacist supplies a maximum quantity or number of units of the pharmaceutical item in the pharmaceutical benefit determined under paragraph 85A(2)(a) of the Act.
(1) A condition is that, when the pharmaceutical benefit is supplied, the approved pharmacist:
(a) records the information that the pharmacist used to support his or her decision to supply the pharmaceutical benefit; and
(b) prepares information about the supply that the pharmacist will send to the PBS prescriber.
Note: See the PSA Guidelines for guidance about when the information should be sent to the PBS prescriber.
(2) The information that must be recorded and prepared includes the following:
(a) a statement that the pharmaceutical benefit supplied is a pharmaceutical benefit determined under paragraph 89A(3)(a) of the Act;
(b) a statement that the conditions mentioned in sections 2.02 to 2.05 are satisfied;
(c) a statement that the approved pharmacist is satisfied that the pharmaceutical benefit needs to be supplied to the person to facilitate continuity of treatment.
(1) For subsection 89A(3)(a) of the Act, an approved pharmacist may supply without a prescription a pharmaceutical benefit, being any listed brand of a pharmaceutical item mentioned in Schedule 1.
(2) For subsection (1), the pharmaceutical item is the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(section 3.01)
Levonorgestrel | Tablets 30 micrograms, 28 | Oral |
Levonorgestrel with Ethinyloestradiol | Pack containing 21 tablets 100 micrograms‑20 micrograms and 7 inert tablets | Oral |
| Pack containing 21 tablets 125 micrograms‑50 micrograms and 7 inert tablets | Oral |
| Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral |
| Pack containing 6 tablets 50 micrograms‑30 micrograms, 5 tablets 75 micrograms‑40 micrograms, 10 tablets 125 micrograms‑30 micrograms and 7 inert tablets | Oral |
Norethisterone | Tablets 350 micrograms, 28 | Oral |
Norethisterone with Ethinyloestradiol | Pack containing 21 tablets 500 micrograms‑35 micrograms and 7 inert tablets | Oral |
| Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral |
| Pack containing 12 tablets 500 micrograms‑35 micrograms, 9 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral |
Norethisterone with Mestranol | Pack containing 21 tablets 1 mg‑50 micrograms and 7 inert tablets | Oral |
Atorvastatin | Tablet 10 mg (as calcium) | Oral |
| Tablet 20 mg (as calcium) | Oral |
| Tablet 40 mg (as calcium) | Oral |
| Tablet 80 mg (as calcium) | Oral |
Fluvastatin | Capsule 20 mg (as sodium) | Oral |
| Capsule 40 mg (as sodium) | Oral |
| Tablet (prolonged release) 80 mg (as sodium) | Oral |
Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral |
| Tablet containing pravastatin sodium 20 mg | Oral |
| Tablet containing pravastatin sodium 40 mg | Oral |
| Tablet containing pravastatin sodium 80 mg | Oral |
Rosuvastatin | Tablet 5 mg (as calcium) | Oral |
| Tablet 10 mg (as calcium) | Oral |
| Tablet 20 mg (as calcium) | Oral |
| Tablet 40 mg (as calcium) | Oral |
Simvastatin | Tablet 5 mg | Oral |
| Tablet 10 mg | Oral |
| Tablet 20 mg | Oral |
| Tablet 40 mg | Oral |
| Tablet 80 mg | Oral |
The endnotes provide details of the history of this legislation and its provisions. The following endnotes are included in each compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnote 5—Uncommenced amendments
Endnote 6—Modifications
Endnote 7—Misdescribed amendments
Endnote 8—Miscellaneous
If there is no information under a particular endnote, the word “none” will appear in square brackets after the endnote heading.
Abbreviation key—Endnote 2
The abbreviation key in this endnote sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended the compiled law. The information includes commencement information for amending laws and details of application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision level. It also includes information about any provisions that have expired or otherwise ceased to have effect in accordance with a provision of the compiled law.
Uncommenced amendments—Endnote 5
The effect of uncommenced amendments is not reflected in the text of the compiled law, but the text of the amendments is included in endnote 5.
Modifications—Endnote 6
If the compiled law is affected by a modification that is in force, details of the modification are included in endnote 6.
Misdescribed amendments—Endnote 7
An amendment is a misdescribed amendment if the effect of the amendment cannot be incorporated into the text of the compilation. Any misdescribed amendment is included in endnote 7.
Miscellaneous—Endnote 8
Endnote 8 includes any additional information that may be helpful for a reader of the compilation.
ad = added or inserted | pres = present |
am = amended | prev = previous |
c = clause(s) | (prev) = previously |
Ch = Chapter(s) | Pt = Part(s) |
def = definition(s) | r = regulation(s)/rule(s) |
Dict = Dictionary | Reg = Regulation/Regulations |
disallowed = disallowed by Parliament | reloc = relocated |
Div = Division(s) | renum = renumbered |
exp = expired or ceased to have effect | rep = repealed |
hdg = heading(s) | rs = repealed and substituted |
LI = Legislative Instrument | s = section(s) |
LIA = Legislative Instruments Act 2003 | Sch = Schedule(s) |
mod = modified/modification | Sdiv = Subdivision(s) |
No = Number(s) | SLI = Select Legislative Instrument |
o = order(s) | SR = Statutory Rules |
Ord = Ordinance | Sub‑Ch = Sub‑Chapter(s) |
orig = original | SubPt = Subpart(s) |
par = paragraph(s)/subparagraph(s) |
|
Name | FRLI registration | Commencement | Application, saving and transitional provisions | |||||
National Health (Continued Dispensing) Determination 2012 | 29 June 2012 (see F2012L01465) | 1 July 2012 |
| |||||
PB 45 of 2013 | 9 Aug 2013 (see F2013L01561) | 10 Aug 2013 | — | |||||
Provision affected | How affected |
Pt 1 |
|
s 1.03................... | am PB 45 of 2013 |
Pt 2 |
|
s 2.01................... | am PB 45 of 2013 |
Pt 3 |
|
s 3.01................... | rs PB 45 of 2013 |
Sch 1 |
|
Sch 1................... | rs PB 45 of 2013 |
Endnote 5—Uncommenced amendments [none]
Endnote 6—Modifications [none]
Endnote 7—Misdescribed amendments [none]
Endnote 8—Miscellaneous [none]